Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes] 

Exploring Blood-Based Biomarkers and Treatment Eligibility in Alzheimer Disease: Gil Rabinovici, MD

Articles

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

Phase 2a Trial to Test Effects of Antiseizure Medication Lamotrigine in Dementia With Lewy Bodies

The epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer discussed the wide-spread applicability of scalp EEG and the potential for machine learning models to help predict epilepsy surgery outcomes. [WATCH TIME: 4 minutes]

Scalability of Scalp EEG as a Tool for Epilepsy Surgery Outcomes: Lara Jehi, MD, MHCDS

For more than a 2-year treatment period, 95% of patients reported taking at least 95% of their daily medications with zilucoplan.

Medication Compliance High With Self-Administered Ziluocoplan in Myasthenia Gravis

The neurologist in the Headache Center at Cleveland Clinic shared her post perspective on the 2024 AHS Scottsdale meeting which highlighted advancements in headache medicine and the growing impact of the field on patient care. [WATCH TIME: 5 minutes]

Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MD

Dean and chief academic officer at the University of Miami Miller School of Medicine.

The dean and chief academic officer at the University of Miami Miller School of Medicine discussed the university’s investment in computational biology to advance aging and neuroscience research. [WATCH TIME: 5 minutes]

Driving Innovation in Aging and Neurodegenerative Research: Henri Ford, MD, MHA 

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

Research from IJMSC September 2024

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

CTAD 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Advances in the Management of Excessive Daytime Sleepiness and Narcolepsy

In this program, sleep experts will discuss the importance of timely and accurate diagnosis, recent approvals and available treatment options for the management of narcolepsy and excessive daytime sleepiness.

Experts provide an overview of excessive daytime sleepiness and narcolepsy.

Narcolepsy  Overview 

Anne Marie Morse, DO, FAASM, discusses the burden and risk factors associated with excessive daytime sleepiness and narcolepsy.

Burden and Risk Factor of Narcolepsy

Experts discuss narcolepsy diagnosis and the challenges associated with it.

Diagnosis of Narcolepsy

Thomas E. Scammell, MD, discusses evaluating excessive daytime sleepiness (EDS).

EDS Evaluation 

Debra Stultz, MD, provides an overview of the available resources that are available for narcolepsy treatment.

Available Resources for Narcolepsy Treatment

Neurology experts describe the goals of therapy for narcolepsy treatment. 

Goals of Therapy for Narcolepsy 

Karl Doghramji, MD, FAASM, DFAPA, provides an overview of the pharmacological treatment options for narcolepsy.

Pharmacological Treatment Options for Narcolepsy

Neurology experts discuss excessive daytime sleepiness (EDS) and narcolepsy treatment options. 

EDS and Narcolepsy Treatment Options

Thomas E. Scammell, MD, provides an overview of the mechanism of action of pitolisant for the treatment of narcolepsy.

Pitolisant: Mechanism of Action

Anne Marie Morse, DO, FAASM, discusses the efficacy and safety profile of pitolisant for the treatment of narcolepsy.

Pitolisant Efficacy and Safety

Experts discuss the efficacy and safety profile of solriamfetol for the treatment of narcolepsy.

Solriamfetol Efficacy and Safety

Experts discuss sodium oxybate and antidepressants for treatment of cataplexy.

Sodium Oxybate and Antidepressants for Treatment of Cataplexy 

Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences. 

Unmet Needs in Narcolepsy and Clinical Pearls

Peer Exchange

Clinical

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Burden and Risk Factor of Narcolepsy

EP: 1.Narcolepsy Overview

EP: 2.Burden and Risk Factor of Narcolepsy

EP: 3.Diagnosis of Narcolepsy

EP: 4.EDS Evaluation

EP: 5.Available Resources for Narcolepsy Treatment

EP: 6.Goals of Therapy for Narcolepsy

EP: 7.Pharmacological Treatment Options for Narcolepsy

EP: 8.EDS and Narcolepsy Treatment Options

EP: 9.Pitolisant: Mechanism of Action

EP: 10.Pitolisant Efficacy and Safety

EP: 11.Solriamfetol Efficacy and Safety

EP: 12.Sodium Oxybate and Antidepressants for Treatment of Cataplexy

EP: 13.Unmet Needs in Narcolepsy and Clinical Pearls